REVIEW

DNA electrotransfer: its principles and an updated review of its therapeutic applications

F André and LM Mir

Laboratory of Vectorology and Gene Transfer, UMR 8121 CNRS - Institut Gustave-Roussy, Villejuif Cedex, France

The use of electric pulses to transfert all types of cells is well known and regiziarly used in vitro for bacteria and eukaryotic cells transformation. Electric pulses can also be delivered in vivo either transculareously or with electrodes in direct contact with the dissues. After injection of naked DNA in a trissue, appropriate local electric pulses can result in a very high expression of the transferred genes. This manuscript describes the evolution in the concepts and the valous

optimization steps that have led to the use of combinations of pulses that fit with the known roles of the electric pulses in DNA electrotransfer, namely cell electropermeabilization and DNA electrophoresis. A summary of the main applications published until now is also reported, restricted to the in vivo preclinical trials using therapeutic genes.

Gene Therapy (2004) 11, S33-S42. doi:10.1038/sj.gt.3302367

Keywords: electrogenetherapy; DNA electrotransfer, nonviral gene therapy; electroporation; electropermeabilization; naked DNA

Introduction

Nonviral gene therapy using the combination of 'physical' approaches and naked DNA is rayidly developing for two main reasons: the use of naked DNA eliminates the limitations and the risks linked to the use of viruses (coding sequence length in the case of the adenovirus associated virus, insertional mutagenesis in the case of the aterovirus, immunological responses in the case of the adenoviruses, etcl and, in spite of extensive research, efficient and safe chemical vectors have not yet been developed for in vivo gene delivery.

There are several physical approaches for nonviral gene therapy. (i) The simplest, of course, is the injection of naked DNA, which in the skeletal or cardiac muscle leads to some expression of the injected genes;1 however, this expression is very low and very variable from sample to sample, (ii) The hydrodynamic method consists in the very rapid injection through the mouse tail vein of a large volumes of DNA solution: it results in a very efficient transfection of liver cells, even though the procedure is somehow dangerous for the treated mice;4-6 indeed, part of the mechanism is based on the transient heart failure resulting from the injection, which blocks the fluid distribution in the body and provokes a liquid overpressure in the liver." (iii) For physical DNA transfer to superficial tissues like the skin or the leaves in the plant kingdom, the 'biolistic' approach ('jet injection' and 'gene gun') also leads to good transfection levels. The commonly termed 'gene gun' consists in a device propelling plasmid-coated gold microparticles.7.8 For the 'jet injection' or 'needle-free' injection, the DNA is pushed at high pressure and high speed through a tiny

orifice at the head of the injector, creating an ultrafine stream of high-pressure fluid that penetrates the skin. "Si (iv) The proof of the concept of sonoporation (use of focused ultrasounds to permeate the cells) has just been developed and still requires further elaboration." (v) DNA electoratassfer has been used with success since 1998 and is becoming a real alternative to the viral methods for in vivo gene transfer.

The use of electric pulses is very popular for the transfection of bacterial and eukaryotic cells in vitino. The initial limitation of the so-called electroporation, a low cell survival, could be overcome by the use of appropriate electric pulses. The technique was then transferred in vivo, and termed DNA electrotransfer or electrogenetherapy. In this article, we present an historical survey of this approach, which will include the description of the bases of cell electropermeabilization and DNA electrotransfer, as well as several consecutive optimization efforts that have led to a very efficient and safe procedure. A summary of the main applications published until now is also reported, restricted to the in vivo preclinical trials using therapeutic genes.

The origin of DNA electrotransfer (the in vitro only period)

The first pioneering demonstration that DNA could be introduced into living cells by means of electric pulses was published by E Neumann in 1982. He built a device with chambers specifically designed for the pulse delivery to the suspension of cells and DNA. More than 2 years were necessary before the publication of the second paper describing successful transfer of DNA to eukaryotic cells in vitro by H Potter in 1984. Since this result

was achieved using a classical (thus accessible) laboratory equipment, the ISCO 494 generator for proteins and DNA gel electrophoresis, many other groups could try this approach. The procedure consisted in creating a short circuit through the cell asspension, which caused the delivery of an exponentially decaying electric pulse to the cells. Since then, devices delivering exponentially decaying pulses have been developed by various companies. However, already in 1985, I Tesissi developed the first square wave pulse generator with outputs compatible with the needs for cell electropermeabilization in vitin. In any case, since 1986, DNA electrotransfer is the most popular way to transfect bacterial cells and one of the good options for the in vitro transfer to a cukaryotic cells as well.

Principles of the DNA electrotransfer

The exposure of living cells to short and intense electric pulses induces position-dependent changes in the transmembrane potential difference. These changes are well described by the equation of Schwann, which indicates that the value of the induced change is proportional to the cell radius and the scalar value of the external electric field (Figure 1). This change will superimpose to the resting transmembrane potential. When the transmembrane potential difference net value (the sum of the vectorial values of the induced and resting potential differences) is greater than 0.2-0.4 V. transient permeation structures are generated at the cell membrane level, because the membrane structure cannot resist the electrocompressive forces due to this potential difference. Electropermeabilization is thus a threshold phenomenon, imposed by the need to overpass a threshold value of the transmembrane potential difference.




Figure 1. Effect of an external electric field applied on a living cell. The external electric field induces a change (4ϕ) in the resting transmembrane potential (4ϕ) or of the cell. The calls of the malaxed change depends on the shape of the cell ψ and the confunctivity of the made $g(\lambda)$. At point M on the cell surface, it is also proportional to the cell malaxe, the scalar value of the external electric field (E) and the cosmus of the angle θ (polar coordinate of ψ) that M.

The structure of these transient permeation structures is not yet elucidated. Some models proposed the generation of 'electropores' (described as 'holes' in the membranes), but cell electropermeabilization can be totally reversible and the theory hardly explains the resealing of these 'electropores'. Recent modelization by molecular dynamics' has suggested that under transmembrane potential differences, much larger than those necessary to obtain the 'physiological' reversible cell electropermeabilization, pores could indeed be generated. Still, the reversible structure remains undefined.

Properties of cell electropermeabilization: cell membrane crossina

Cell electropermeabilization is a general phenomenon that can be obtained in the cells of archaebacteria. eubacteria and eucaryota phyla. Indeed, all living cells are limited by a nonconductive membrane that isolates the internal conductive medium from the external medium. Thus, all cells will react to external electric fields by the induction of a transmembrane potential difference that, above a threshold value, will provoke the membrane destabilization. Under appropriate electrical parameters, this destabilization will be totally reversible, ensuring the survival of the transiently permeabilized cell. Owing to the use of very short pulses, cell electropermeabilization is a nonthermal phenomenon: this characteristic contributes to its reversibility (no denaturation of the membrane proteins, even though one of the cell electropermeabilization early models, which was not validated, considered protein denaturation as the primum movens of the membrane properties changes). Finally, the most interesting property of the cell electropermeabilization, which supports several biomedical and biotechnological applications, is the fact that cell electropermeabilization allows the direct delivery of nonpermeant molecules inside the cell cytoplasm, bypassing the normal internalization route for these molecules (usually the endocytosis pathway). Small nonpermeant molecules can enter the electropermeabilized cells by diffusion through the transiently permeabilized cell membrane, while large nonpermeant molecules like DNA enter by other mechanisms as discussed below.

In vivo delivery of electric pulses

Before the in viru delivery of electric pulses in the frame of the electrogenetherapy, other applications of the in viru cell electrogenetherapy, other applications of the in viru cell electrogenetherapy. The pulse of the inverted electric pulses in viru to rabbit comea, in order to five human Hela cells to the cells of the cornea. Cell electrofusion, in viru, is the consequence of the electropermeabilization of two adjacent cells or of the fact that two previously electropermeabilized cells are brought in close contact. In 1988, it was found that bleomycin toxicity is several hundreds of thousands times higher on electropermeabilized cells than on cells unexposed to the electric pulses. This increase in toxicity was also found in preclinical experiments in which permeabilizing electric pulses were delivered transcutaneously to

transplanted." or spontaneous tumours in mice." Moreover, because of the antitumour efficacy of this approach, clinical trials were rapidly performed.\(^{2.98}\) This approach, clinical trials were rapidly performed.\(^{2.98}\) This approach was termed electrochemotherapy, and the pulse conditions, used fin almost all the published clinical irials.\(^{2.98}\) were eight identical square wave pulses of 100 ps and 1300 V/cm at a repetition frequency of 11½ using external electrodes (transcutaneous pulses). These trials demonstrated that it is possible to deliver in wire electric pulses to animals and patients and they greate facilitated the development of the in vine DNA electro-

Indeed, in parallel, Jon Wolff showed in 1990¹ that direct injection of naked DNA in skeletal muscle in vize results in gene expression at low and variable levels. Thus, it seemed tempting to combine the injection of DNA and the electric pulses delivery.

In 1991, Titomirov et al28 delivered exponentially decaying short pulses to skin after myc and ras genes injection and they were able to recover a few growing cells expressing myc and ras proteins that could, eventually, reflect the in vivo electrotransfer of these oncogenes. In 1996, Heller et ales delivered electrochemotherapy-type trains of short pulses (100 us) to the liver after the injection of reporter genes DNA, with good levels of transfection that nowadays could also be partly explained by the injection itself, taking into account the results of the hydrodynamics method. In 1998, four groups, in three different tissues, consistently demonstrated good transfection levels using long pulses (5–50 ms): MP Rols and J Teissié in tumours, 50 Suzuki et al in the liver,31 and Aihara and Miyazaki,22 and Mir et. al73 in the skeletal muscle. The use of trains of several identical pulses in the milliseconds to tens of milliseconds duration range actually results in a highly significant increase in the level of expression of the reporter genes coded by the naked DNA injected in the target tissues. Later on, Lucas and Heller compared short and long pulses, demonstrating that the level of expression was higher, and expression duration longer, when long pulses were delivered into the tissues.

Use of trains of identical electric pulses for efficient DNA electrotransfer in skeletal muscle

The earliest and most exhaustive series of experiments allowing to understand the mechanisms of DNA electrotransfer as well as to optimize such trains of identical electric pulses were reported in 1999.36 Experiments analysed the respective influence of the pulse duration, voltage applied (or more precisely of the applied voltage to electrodes distance ratio), number of pulses and repetition frequency. Using the gene coding for the firefly luciferase, an increase of 200 times of the expression with respect to the naked DNA injection alone was shown, a large decrease in the variability of this expression, as well as a long-term expression since the high level of expression remained stable for at least 9 months. In the mouse skeletal muscle, using external electrodes (transcutaneous electric pulses) and trains of identical electric pulses, optimal conditions are eight pulses of 20 ms and 200 V/cm at a repetition frequency of 1 or 2 Hz, delivered after the intramuscular injection of the DNA).^{36,57} These conditions have been adapted to other tissues: in tumours, transfection levels that depended on the tumour type were found maximal using eight identical pulses of 20 ms and 500 or 600 V/ cm at a repetition frequency of 1 or 2 Hz/²⁰ 250 V/cm in the liver,⁷⁶ and 500 or 750 V/cm for the skeletal muscle in neonate mice (7-10 days old mice).⁸⁰

Roles of the electric pulses in DNA electrotransfer

Experiments showed that, after the electric pulses delivery, tissues remain permeabilized for several minutes ^{30,4,4,2} Moreover, for an efficient transfer, DNA must be injected before the electric pulses delivery. Thus, permeabilization of the cells is not sufficient even though it is necessary since efficient electrotransfer requires sufficiently intense electric fields (above cell permeabilization throat policy). The proposed is a considered to the cells are the electrotransfer requires sufficiently long pulses. The mechanism of DNA electrotransfer could not be just cell electropermeabilization and DNA diffusion through the permeabilized plasma membrane.

The role of the electric pulses in DNA electrotransfer has then been studied using combinations of pulses. Instead of delivering trains of eight identical pulses (of 20 ms and 200 V/cm, at a repetition frequency of 1 Hz), cells were exposed to:

• 1FV (high voltage, short pulse) of 100 µs at 800 V/cm (an electrochemotherapy-like pulse, with a field strength adapted to the skeletal muscle, the muscle fibres having a diameter larger than the average diameter of the tumour cells; using eight of such pulses at 1 Hz repetition frequency. Gehl et all showed that this field strength was the highest that one could deliver to the muscle fibres without provoking their irreversible electropermeabilization).

 1 or several LV (low voltage, long pulse) of 100 ms at 80 V/cm (nonpermeabilizing pulses, of a field intensity below the threshold for reversible permeabilization in the mice skeletal muscle).⁵⁰

followed by

The first experiments were performed using two classical square wave generators, with LV of 85ms, a limitation imposed by the devices used, and a manual switch to deliver the LV(s) after the IV.⁴⁵ Then a device for the controlled generation of such combinations of HV and LV pulses, with, moreover, a controlled gap between the HV and LV pulses, was prepared by the Faculty of Electrical Engineering of the University of Ljubijana, based on a previously developed electroproator. With such an equipment, the roles of the electric pulses in DNA electrotransfer could actually be analysed.

The efficacy of several combinations of pulses (I HV alone, or 1 HV followed by 1 LV, or 1 HV followed by 4 LV) was compared. ** It was shown that the duration of the high permeabilized state of the muscle fibres was the same for the three combinations tested, all of them including the same HV pulse. On the contrary, the authors found that efficacy was only achieved if at least



Figure 2 The Cliniporator. This new pulse generator (Cliniporator) IGEA s.r.l., Carpi, Italy) has been developed within the Cliniporator project (QLK3-1999-00484) of the 5th Framework Program of the European Union. It delivers combinations of HV and LV pulses.

an LV was delivered after the HV. They also reported that the efficacy of a single LV could be observed even if this LV was delivered up to 100 s after the HV, while in the case of the delivery of 4 LV, efficacy could be achieved even if the 4 LV were delivered up to 3000 s after the HV. Since almost no efficacy was found with the LV alone, the conclusions of the authors were that the HV pulses delivery (permeabilizing pulses) were mandatory, but that the efficacy of the procedure was brought by the LV pulses. Other arguments have contributed to point out that the long LV pulses act on DNA, provoking its electrophoretic displacement.45

The electric pulses thus have two roles, the 'electroporation' of the target cells and the electrophoretic transport of the DNA 'towards or across' the cell membrane. Target cell electropermeabilization is mandatory, but the electrophoretic component of the electric pulses is actually instrumental in DNA electrotransfer efficacy.

These combinations have been studied within the Cliniporator project (QLK3-1999-00484) of the 5th Framework Program of the European Union. Moreover, a new pulse generator (Cliniporator ", IGEA s.r.l., Carpi, Italy), able to deliver these combinations of pulses, has been developed within this project (Figure 2). In the skeletal muscle and the skin, appropriate pulses parameters have led to a further increase of the expression of the luciferase coding plasmid with almost no histological modification.

Interests of DNA electrotransfer

In vitro, DNA electrotransfer is interesting because it is based on cell electropermeabilization, which is the perturbation of cell membrane impermeability by physical means, with neither addition nor withdrawal of membrane components as it happens when chemical permeabilization means are used. Thus, full recovery is facilitated. Moreover, if actually controlled, cell electropermeabilization is a nonthermal effect, without protein denaturation (which also facilitates cell recovery). Moreover, the method is simple, since it only requires to mix the cells and the DNA and to pulse the mixture.

In vivo, DNA electrotransfer is also interesting because it allows the transfer of genes into tissues without using virus. Moreover, no chemical method works in vivo better than the direct electrotransfer of the naked DNA. The method is also very rapid: the new constructs made by usual molecular biology approaches can be amplified by rapid 'minipreparations' of DNA and quantified by optical density determination; then it is sufficient to adjust plasmid concentration, to inject, and to 'pulse' (with viral methods, constructs must be inserted in a viral background, transfected in producing cells, and then virions must be produced, collected, isolated, concentrated and titrated before they could be injected).

Therapeutical applications already developed in preclinical trials

Tables 1 and 2 summarize the result of an extensive search for publications reporting the in vivo delivery of genes of therapeutic interest by means of DNA electrotransfer. Publications using only reporter genes have not been included in the tables. Experiments have been classified according to the main applications foreseen by their authors.

Most of the experiments deal with gene transfer to the skeletal muscle in mice. However, gene transfer to tumours, brain, lumbar intrathecal space, skin, liver, cornea, brain, penile corpora cavernosa and seminiferous tubes have also been reported. Experiments, mainly in mice (about 80% of the publications) have also been performed in rats, pigs, rabbits, guinea pigs, sheep, goats, dogs and cattle. These experiments also demonstrate the safety of the procedure, the possibility to repeat the treatment (shown already in 1999 by Rizzutto et al120), as well as the possibility to coelectrotransfer up to three plasmids into the same skeletal muscle fibres.85 The main general application is immunotherapy (48%; 54/113). Cancer treatment (38%; 43/113), metabolic disorders or metabolism modification (17%; 19/113) and correction of organ or site-specific diseases (14%: 16/113) are the three other frequent applications. Monogenetic diseases (9%: 10/113), cardiovascular diseases (9%; 10/113) and analgesia (2%; 2/113) are other applications also found in the literature.

It must be noted that each of these applications includes the use of a large variety of genes. In this respect, it is necessary to point out that the genes of proteins involved in the immune system responses have been the most usually transferred genes for vaccination, cancer, treatment of arthritis, immunological protocols, etc. These genes include those coding for the IL-2, IL-4. IL-10, IL-12, IL-18, IL-18 binding protein, soluble TNF receptor, GM-CSF, tumour epitopes, the HIV gag gene, recombinant monoclonal antibodies, mycobacterial antigens, etc. The details are listed in the Table 2. In fact, this observation must be related to the fact that in many cases the transfected tissue is the skeletal muscle, used as a cell factory for the production of factors that will act systemically on distant targets.

Therapeutic levels have been achieved. For example, in the case of the gene coding for the erythropoietin

Applications	Dismess	Goues	Tissues	Animals	Ref.
Analgesia 2 Canter 43	Analgesia 2. Cancer 43	PCMC (proop/condanocortity) B.2: U-12: II-18; INF o; GM-CSF, CpG containing DAA-full TR2: to estimose deplicate in containing IMF pS3; bd-sex MRD; a missens VGEF; HR-1 VGEF recoploor, metaggid toe (MRC-15); Staf 3 variant; K1 S; K1- 14.Kc. antecomy	Intrathecal space Muscle, tumour, skin, liver	Rat Mouse, rat	34, 48-87, 101, 102
Cardiovascular diseases 10	Alberosclerosis 2	Prixes, encreasing B-72, Human plasma platelet-activating factor acetylbydrolase (PAE-AFF)	Muscle	Mouse	98, 89
	Ischaenna 4	M10; E18; NF-88 binding sites containing DNA; bVEGP-A and fVEGF-8, protein-disasfide fromerase	Muscle, right himporamous	Mouse, rat	86-68
Immuno-therapy 54	Myocarditis 4 See Table 2	8.1-ra ; 11-10 See Table 2	Muscle See Table 2	Mouse, rat See Table 2	6497
Metabolic disorders 19	Anaemia 10 Diabetes 6	Epo; dimethe erythroputetin fusion protein Bs; insulin precursors, endelivery of B7-1 and PPins or CHA: 1778.5	Muscle, skin Muscle	Munse. rat Mouse	113 – 122 123 – 128
Monogenetic diseases 10	Neuropathy 1 Finombocytopenia 2 Finanseemia 2 Finanseemia 2 Finanseemia 2 Finanseemia 2 Finanseemia 3 Micopalysaccharidosis 1 Myodysthrophy 5	NT3 startoftuophin3 Recombinant human thrombepoieth (th'ipu) Beo Po Foton College Coll	Muscle Muscle Muscle Muscle Muscle Muscle	Mouse Mouse Mouse Mouse Mouse	129 130, 131 132, 133 134 135 135 136–140
Organ- or fisauc-specific diseases 16	Neuron degeneration 1 Arthritis 6 Bone formation 1 From thousany	Cardinhoophin Cardinhoophin Respon Respon Respon Refl Refl Refl Refl Refl Refl Refl Refl	Musche Musche Musche Musche	Mouse, rat Mouse Mouse Mouse	40 95, 141–145 146 112
	Erectile dyshuwtion 1	Neuronal NOS (nitric toxide synthase), penile NOS	Pentle corpora	Rat	147
	Gastric disorders 1 Kidney regeneration 1	Castrin ECE	cavernoss Mascle Muscle	Mouse, rat Rat	148
	Liver regeneration 2 Musch regeneration 2 Ocular diseases 1	RGF IGP-J Hunan IFA (dissue plasminogen activator)	Muscle Muscle Corneal	Mouse, rat Mouse Rat	150, 151 126, 152 153
	Spermatogenesis reame 1	Stem cell factor (SCF) cytoplasmic domain	Seminiferans tubules	Mouse	134

"Number in hold letters corresponds to the number of publications concerning the application or disease.

113

Applications*	Discussor	Genes	Tissurs	Animals	Ref.
Cancer 27	Cancer 27	E2, R72, B18, INF or CpG containing DNA, GM- CSF, R.174, Rakt, TRP2, or entitions	Muscle, tumour, skin	Mouse	34, 48-70, 76, 101,
Cardiovascular diseases 7	Athenyckrosis 1 ischaenia 2	H-12 H-10; H-18	Muscle Muscle	Mouse	88 88 88 88
	Myocarditis 4	IL-1a; II10	Mascle	Mouse, rat	26-62
Metabolic disorders 2	Diabetus 2	IL-4: Codelivery of B7-1 or 87-1 wa	Muscle	Mouse	123, 125
Organ- or tissue-specific diseases 6	Bronchopusmonary hypereactivity 1	01-30		Monse	112
	Arthritis 5	il10; sofuble p75 TNF receptor linked to the Fc portion of human IgC1 (sTNFR:Fc)	Muscle	Mense, rat	95, 142143
Vaccination 12		IMF or 1188-Aty 14A influenza virus; HIV gag; Japanese enceptalitis virus; mycobacterial attigenes; recombinant rackb; chains of the Tg10 mense mAb; chimeric hepatitis C. virus erroz, glycoproten; Blo 13	Muscle, skin	Monse, pig, sheep, goats, cattle, rabbit. guinea pig	98~100, 103~111

Numbers in bold letters correspond to the number of publications concerning the application or disease.

(epo), hematocrit increase has been achieved in many cases (Table 1). Expression of electrotransferred minidystrophin gene in the altered myodystrophic muscles of the mdx mice has been demonstrated (Table 1). The electrotransfer of the genes coding for antioangiogenic factors has demonstrated distant antitumour effects as weil as antimetastatic effects in the murine model consisting in the intravenous injection of B16F10 cells. 40.85 Noticeable concentrations of the cytokines Interleukin-2 and GM-CSF in tumours transfected with the corresponding genes have been measured.50 The biological effects observed in the publications listed in Table 1 demonstrate the efficacy of the electrogenetherapy for the treatment of various diseases.

Finally, DNA electrotransfer has also been used for biotechnological purposes. For example, the electrotransfer of the human erythropoletin gene in the oviduct of laying hens has also been carried out for the production of the human erythropoietin, 155 and the transfer of the growth hormone-releasing hormone has also been successfully performed in pigs, not for the treatment of a pig disease but for the achievement of an enhanced weight gain and improved body composition. 186-188

Conclusion

In conclusion, DNA electrotransfer or electrogenetherapy constitutes a real alternative to viral approaches for gene transfer in vivo. Its officacy is proven and there is no doubt on its biological safety. Moreover, DNA preparation is easy and secure, the roles of the electric pulses are described, the control of transfer conditions is achievable and appropriate equipment is available.

Acknowledgements

We acknowledge the financial support of CNRS, IGR, AFM and the EU Commission through the projects Cliniporator (QLK3-1999-00484)189 and Esope (QLK3-2002-02003) coordinated by LMM. We also acknowledge all their colleagues for fruitful discussions and collaborative work. FA is the recipient of an 'aide aux études' from the AFM (Association Française contre les Myopathies).

References

- 1 Wolff JA et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
- 2 Budker Vet al. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J Gene Mad 2000; 2:
- 3 Satkauskas S. Bureau MP. Mahfoudi A. Mir LM. Slow accumulation of plasmid in muscle cells, supporting evidence for a mechanism of DNA uptake by receptor-mediated endocytosis. Mol Ther 2001; 4: 317-323.
- 4 Lin F, Song Y, Liu D. Flydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Therapy 1999; 6: 1258-1266.
- 5 Liu F, Huang L. Improving plasmid DNA-mediated liver gene transfer by prolonging its retention in the hepatic vasculature. I Gene Med 2001: 3: 569-576.

- 6 Zhang G et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Therapy 2004; 33: 675-682.
- Udvardi A et al. Uptake of exogenous DNA via the skin. J Mol Med 1999: 77: 744–750.
- 8 Godon C, Caboche M, Daniel-Vedele F. Transient plant gene expression: a simple and reproducible method based on flowing particle gun. Biochimie 1993: 75: 591-595.
- 9 Furth PA, Shamay A, Wall RJ, Hennighausen L. Gene transfer into somatic tissues by jet injection. Anal Biochem 1992; 205: 365-368.
- 10 Walther W et al. Intratumoral low-volume Jet-injection for efficient nonviral gene transfer. Mal Biolecimol 2002; 21: 105-115.
 11 Wang G et al. Ultrasound-guided gene transfer to hepatocytes
- in utero. Fetal Diagn Ther 1998; 13: 197-205.
 Neumann E, Schaeter-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982; 1: 941-945.
- 13 Potter H, Weir L, Leder P. Enhance-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci USA 1984; 81: 761-7165.
- 14 Puc M et al. Techniques of signal generation required for electropermeabilisation Survey of electropermeabilisation during Replective Immistra 2004, 64, 112–224.
- devices. Bioelectrochemistry 2004, 64: 113-124.

 15 Zerbib D, Amalric F, Teissie J, Electric field mediated transformation: isolation and characterization of a TK+
- subclone. Biochem Biophys Res Commun 1985; 129: 611–618.
 16 Tieleman DP, Leontiadou H, Mark AE, Marrink SJ. Simulation of pore formation in lipid bilayers by mechanical sixess and electric fields. J Am Chem Soc 2005; 125: 6382–6883.
- 17 Tsong TY, 5u ZD. Biological effects of electric shock and heat denaturation and oxidation of molecules, membranes, and cellular functions. Ann NY Acad Sci 1999, 888: 211–232.
- 18 Grasso RJ, Heller R, Cooley JC, Haller BM. Electrofusion of individual animal cells directly to intact corneal epithelial tissue. Biochim Biophys Acta 1989; 980: 9-14.
- 19 Heller R, Grasso RJ. Transfer of human membrane surface components by incorporating human cells into intact animal tissue by cell-tissue electrofusion in vivo. Biochim Biophys Acta 1990; 1024: 185–188.
- 20 Orlowski S, Belehradek Jr J, Paoletti C, Mir LM. Transient electropermeabilisation of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988; 37: 4727–4733.
- 21 Mir LM, Orlowski S, Beleitradek Jr J, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur. J Cancer 1991; 27: 68–72.
- Belehradek Jr. J. et al. Electrochemotherapy of spontaneous mammary turnours in mice. Eur J Caneer 1991; 27: 73-76.
- Mir LM et al. Electrochemotherapy, a new antitumor treatment: first clinical trial. C R Arad Sci III 1991; 313: 613-618.
 Belehradek M et al. Electrochemotherapy, a new antitumor
- treatment. First clinical phase I-II trial. Cancer 1993; 72: 3694-3700.

 25 Mir LM et al. Effective treatment of cutaneous and
- subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998; 77: 2336-2342. 26 Gothelf A. Mir LM, Gehl J. Electrochemotherapy: results of
- cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29: 371–387. 27 Seria G. Cemazar M. Rudolf Z. Electrochemotherapy:
- advantages and drawbacks in treatment of cancer patients.

 Cancer Ther 2003; 1: 133–142.

 28 Thombres AV Sukharas S. Kietanasa E. In proceedings of the cancer participation.
- 28 Titomirov AV, Sukharev S, Kistanova E. In vivo electroporation and stable fransformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1991; 1068: 131–134.
- 29 Heller R et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett 1996: 389: 225-228.

- 30 Rols MP et al. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998; 16: 168–171.
- 31 Suzuki T et al. Direct gene transfer into rat liver cells by in vivo electroporation. FEBS Lett 1998; 425: 436–440.
- electroporation. FEBS Leit 1998; 425: 436-440.

 32 Alhara FI, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-870.
- 33 Mir LM et al. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer Into skeletal muscie. C R Acad Sci III 1998; 321: 893–899.
- 34 Lucas ML, Heller R. Immunomodulation by electrically enhanced delivery of plasmid DNA encoding iL-12 to murine skeletal muscle. Mol Ther 2001; 3: 47–53.
- skeietai muscie. Mol Ther Alla; 3: 47–33.
 35 Mir LM et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4767-4767.
- 36 Gehl J, Mir LM. Determination of optimal parameters for in vive gene transfer by electroporation, using a rapid in vive test for cell permeabilization. Biochem Biophys Res Commun 1999; 261: 377–380.
- 37 Cehi J et al. in vwo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acis 1999, 1428: 233–240.
- Bielectrochemistry 2000; 52: 83-90.
- 39 Liu F, Huang L. Electric gene transfer to the liver following systemic administration of plasmid DNA. Gene Therapy 2002; 9: 1116–1119.
- 40 Lesbordes JC et al. In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neutron degeneration in pmn mice. Flum Mol Genet 2002; 11: 1615–1625.
- 41 Gehl J. Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochim Biophys Acta 2002; 1569: 51–68.
- 42 Satkauskas S et al. Mechanisms of in vivo DNA electrotransfer, respective contributions of cell electropermeabilisation and DNA electrophoresis. Mol Ther 2002; 5: 133–140.
- 43 Bureau MF et al. Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochim Biophys Acta 2000; 1474: 353-359.
 44 Puc M. Filsar K. Rebersek S. Miklavski: D. Electroporator
- 44 Pulc M, Pilsar K, Rebersek S, Missiwck D. Electroporator for in vitro cell electropermeabilisation. Radiol Oncol 2001; 35: 203–207.
- 45 Zaharuff DA, Barr RC, Li CY, Yuan F. Electromobility of plusmid DNA in tumor tissues during electric field-mediated gene delivery. Gene Therapy 2002; 9: 1256–1250.
- 46 Lin CR et al. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Therapy 2002; 9, 1247–1253.
- 47 Lee TH et al. In vivo electroporation of proopiomelanocortin induces analyssia in a formalin-injection pain model in rats. Pain 2008; 104: 159-167.
- 48 Yu DS, Lee CE Hsieh DS. Chang SV. Antifumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Uralogy 2004; 63: 596–601.
- Heller LC, Coppola D. Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Therapy 2002; 9: 1321–1325.
- 50 Kalat M et al. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Cancer Res 2002: 62: 5489-5494.
- 51 Tamura T et al. Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer. Hum Gene Ther 2001; 12: 1265–1276.
- 52 Tanaka M et al. Inhibition of RL male 1 tumor growth in BALB/c mice by introduction of the RLakt gene coding for antigen recognized by cytotoxic T-lymphocytes and the GM-CSF gene by in trito electroporation. Cancer Sci 2004; 95: 154-159.

- 53 Yamashita YI et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 2001; 63: 1005-1012.
- 54 Lee CF, Chang SY, Hsieh DS, Yu DS, Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy. Cancer Gene Ther 2004; 11: 194-207.
- 55 Lee CF, Chang SY, Hsieh DS, Yu DS. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. J Urol 2004; 171: 1343-1347
- 56 Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vive electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002; 5: 668-675
- 57 Matsubara H et al. Electroporation-mediated transfer of cytokine genes into human esophagesi tumors produces antitumor effects in mice. Anticancer Res 2001; 21: 2501-2503.
- 58 Heller R et al. Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. DNA Cell Biol 2001; 20: 21-26.
- 59 Heller L et al. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 2000; 10: 377-583.
- 60 Kishida T et al. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Therapy 2001; B: 1234-1240.
- 61 Kishida T et al. Electrochemo-gune therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 2003; 8: 738-745.
- 62 Li S et al. Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site. Gene Therapy 2001; 8: 400-407.
- 63 Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. I Natl Cancer Inst 2002; 94: 762-768.
- 64 Li S, Xia X, Zhang X, Suen J. Regression of tumors by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Therapy 2002; 9: 390-397.
- 65 Zhang GH et al. Gene expression and antitumor effect following im electroporation delivery of human interferon alpha 2 gone, Acia Pharmacol Sin 2003; 24: 891-896.
- 66 Lucas ML, Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma, DNA Cell Biol 2003; 22: 756-763.
- 67 Tamura T et al. Combination of fL-12 and iL-18 of electro-gene therapy synergistically inhibits tumor growth. Anticancer Res 2003; 23: 1173-1179.
- 68 Chi CH, Wang YS, Lai YS, Chi KH. Anti-tumor effect of in vivo IL-2 and GM-CSF electrogene therapy in murine hepatoma model. Anticancer Res 2003; 23: 315-321.
- 69 Heller LC et al. Effect of electrically mediated intratumor and intramuscular delivery of a plasmid encoding IFN alpha on visible 816 mouse melanomas. Technol Cancer Res Treat 2002; 1:
- 70 Lee SC et al. Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene. J Biomed Sci 2003: 10: 73-86.
- 71 Baba M, lishi H, Tatsuta M. Transfer of bci-xs plasmid is effective in preventing and inhibiting rat hepatocellular carcinema induced by N-nitrosomorpholine. Gene Therapy 2001; 8, 1149-1156.
- 72 liang Y et al. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001; 61: 2365-2370.

- 73 Goto Tet al. Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene, Proc Natl Acad Sci USA 2000; 97: 354-359.
- 74 Mikata K et al. Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation. Mol Cancer Ther 2002; 1: 247-252.
- 75 Shibata MA, Morimoto I, Otsuki Y, Suppression of imprine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vion electroporation. Cancer Gene Ther
- 2002; 9; 16-27. 76 Hsleh YH et al. Electroporation-mediated and EBV LMPIregulated gene therapy in a syngenic mouse tumor model. Cancer Gene Ther 2003; 10: 626-636.
- 77 Cemazar M et al. Effects of electrogenetherapy with p53wt combined with cisplatin on curvival of human tumor cell lines with different p53 status. DNA Cell Biol 2003; 22: 765-775.
- 78 Ivanov MA et al. Enhanced antitumor activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy, J Gene Med 2003; 5: 893-899.
- 79 Slack A et al. Antisense MBD2 gene therapy inhibits tumorigenesis. J Gene Med 2002; 4: 381-389.
- 80 Shibata MA, Horiguchi T, Morimoto J, Otsuki Y. Massive apoptotic cell death in chemically induced rat urinery bladder carcinomas following in situ HSVtk electrogene transfer. I Gene Med 2003; 5: 219-231,
- \$1 Wang F et al. Inhibition of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway). Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002: 34:
- 82 Yoshizato K et al. Gene delivery with optimized electroporation parameters shows potential for treatment of gliomas. Int J Oncol 2000: 16: 899-905
- 83 Trochon-Joseph V et al. Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res 2004; 64: 2062-2069.
- 84 Niu G et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma 316 tumor in vivo. Cancer Res 1999: 59: 5059-5063.
- 85 Martel-Renoir D et al. Coelectrotransfer to skeletal muscle of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effect. Mol Tur 2003; 8: 425-433.
- 86 Cichon Tet al. Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther 2002; 9: 771-777
- 87 Matsubara H et al. Combinatory anti-tumor effects of electroporation-mediated chemotherapy and wild-type p53 gene transfer to human esophagoal cancer cells. Int J Oncol 2001; 18: 825-829.
- 88 Maliat Z et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001; 89: E41-E45.
- 89 Hase M, Tanaka M, Yokota M, Yamada Y. Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle. Prostaglandins Other Lipid Mediators 2002; 70:
- 90 Silvestre IS et al. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ Res 2000;
- 91 Tanaka S. Uehara T. Nomura Y. Up-regulation of proteindisulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. I Biol Chem 2000: 275: 10368-10393.

- 92 Mailat Z et al. Interleukin-18/interleukin-18 binding protein signaling modulates ischemia-induced neovascularization in mice hindimb. Circ Res 2002: 91: 441–448.
- 93 Silvestre JS et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 2003; 93: 114–123.
- 94 Adachi O et al. Gene transfer of Fe-fusion cytokine by in vivo electroporation: application to gene therapy for viral myocarditis. Gene Therapy 2002; 9: 577–583.
- 95 Deleuze V, Scherman D, Bureau MF. Interleukin-10 expression after inframuscular DNA electrotransfer. kinetic studies. Biochem Blophys Res Commun 2002; 299: 29-34.
- 6 Nakano A et al. Cytokine gene therapy for myocarditis by in vivo electroporation. Hum Gene Ther 2001; 12: 1289-1297.
- 97 Watanabe K et al. Protection against autoimmune myocarditis by gene transfer of interleukin-10 by electroporation. Circulation 2001; 104: 1098-1100.
- 98 Babiuk S et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002; 20: 3399–3408.
- 99 Bachy M et al. Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine 2001: 19: 1688–1693.
- 100 Nomura M et al. In vivo induction of cytotoxic T lymphocytes specific for a single epitope introduced into an unrelated molecule. J Immunol Methods 1996; 193: 41–49.
- molecule. J Immunol Methods 1996; 193: 41—49.
 101 Paster W et al. In vino plasmid DNA electroporation genurates exceptionally high levels of epitope-specific CD8+ T-cell responses. Gene Therapy 2003; 10: 717–724.
- 102 Peretz Y, Zhou ZF, Halwani E, Prud'homme GJ. In vivo generation of dendritic cells by intramiscular codelivery of PLT3 ligand and GM-CSF plasmids. Mol Ther 2002; 6: 407-414.
- 103 Selby M et al. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000; 83: 147–152.
- 104 Tjelle TE et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther 2004; 9: 328-336.
- 105 Tollefsen S et al. DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand J Immunol 2003; 57: 229–238.
- 106 Widera G et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635–4640.
- 107 Zucchelli S et al. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 2000; 74: 11598–11607.
- 109 Yang L et al. Generation of monoclonal antibodies against Blo t3 using DNA immunization with in vivo electroporation. Clin Exp. Allergy 2003; 33: 663–668.
- 109 Wu CJ, Lee SC, Huang HW, Tao MH. In vivo electroporation of skeletal muscles increases the efficacy of Japanese encephalitis virus DNA vaccine. Vaccine 2004; 22: 1457–1464.
- 110 Aurisicchio L et al. Tamarin alpha-interferon is active in mouse liver upon intramuscular gene delivery. J Gene Med 2001; 3: 394–402.
- 111 Perez N et al. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther 2004; 2: 2.
- 112 Deleuze V et al. LPS-induced bronchial hyperreactivity: interference by miL-10 differs according to site of delivery. Am J Physiol Lung Cell Mol Physiol 2004; 286: 1.98–L105.
- 113 Maruyama H et al. Long-term production of crythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats. Gene Therapy 2001; 8: 461-468.
- 114 Maruyama H et al. Skin-targeted gene transfer using in vivo electroporation. Gene Therapy 2001; 8: 1808–1812.
- 115 Nordstrom JL. The antiprogestin-dependent GeneSwitch system for regulated gene therapy. Steroids 2003; 68: 1085–1094.

- 116 Ataka K et al. Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure. Am J Nephrol 2003; 23: 115,222
- 117 Kreiss P, Bettan M, Crouzet J. Scherman D. Erythroposetin secretion and physiological effect in mouse after inframuscular plasmid DNA electrotransfer. J Gene Med 1999; 3: 245–250.
- 118 Rizzuto G et al. Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. Hum Gene Ther 2000; 11: 1891–1900.
- 119 Terada Y et al. Efficient and ligand-dependent regulated erythropoietin production by naked DNA injection and in vivo electroporation. Am J Kidney Dis 2001; 38: 550-53.
- 120 Rizzuto G et al. Efficient and regulated erythropotetin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 1999; 96: 6417-6422.
- 121 Dalle B et al. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood 2001; 97: 3776–3782.
- 122 Lamartina S et al. Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. Hum Gene Ther 2002; 13: 159–210.
- 123 Horiki M et al. High-level expression of interleukin-4 following electroporation-mediated gene transfer accelerates Type 1 diabetes in NOD mics. J Autoimman 2003; 20: 111–117.
- 124 Martinenghi S et al. Human insulin production and amelioration of diabetes in mice by electrotransfer-enhanced plasmid DNA gene transfer to the skeletal muscie. Gene Therapy 2002; 9: 1429–1427.
- 125 Prud'homme GJ, Chang Y, Li X. Immunofnhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Hum Gene Ther 2002; 13: 395-406.
- 126 Yin D, Tang JG. Gene therapy for streptozotocin-induced diabetic nuce by electroporational transfer of naked human insulin precursor DNA into skeletal muscle in vivo. FEBS Lett 2001; 495: 16–20.
- 127 Wang LY, Sun W, Chen MZ, Wang X. Intramuscular injection of naked plasmid DNA encoding human preproinsulin gene in streptozotocin-diabetes mice results in a significant zeduction of blood glucose level. Sheng Li Xue Bao 2003; 85: 661–647.
- 128 Rabinovsky ED, Draghia-Akli R. Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis. Mol Ther 2004; 9: 46–55.
- 129 Pradat PF et al. Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer. Hum Gene Ther 2001; 12: 367–375.
- 130 Zang WP et al. Transfer and expression of recombinant human thrombopoletin gene in COS-7 Cells and raice in vivo. Zhonggue Shi Yan Xue Ye Xue Za Zhi 2001; 9: 14-17.
- 131 Zang WP, Wei XD, Wang SW, Wang DB. Thrombopoletic effect of recombinant human thrombopoletin gene transferred to mice mediated by electric pulse on normal and experimental thrombocytopenia mice. Zhonghua Xue Ye Xue Za Zhi 2001; 22: 128-131.
- 132 Payen E et al. Improvement of mouse beta-thalassemia by electrotransfer of erythropoietin cDNA. Exp Hematol 2001; 29: 298–300.
- 133 Samakoglu Ś et al. betaMinor-głobin messenger RNA accumulation in reticulocytes governs improved erythropoiesis in beta thalassemic mice after erythropoietis complementary DNA electrotransfer in muscles. Bload 2001; 97: 2213–2220.
- 134 Fewell JG et al. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol Ther 2001; 3: 574–583.
- 135 Tomanin R et al. Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome). Acta Paediatr Suppl 2002; 91: 100-104.
- 136 Goilins H, McMahon J, Wells KE, Wells DJ. High-efficiency plasmid gene transfer into dystrophic muscle. Gene Therapy 2003; 10: 504–512.

- 137 Vilquin JT et al. Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Theraps 2001; 8: 1097–1107.
- 138 Murakami T et al. Full-length dystrophin cDNA transfer into skeletal muscle of adult mdx mice by electroporation. Muscle Nerve 2003; 27: 237–241.
- 139 Briguet A et al. Transcriptional activation of the utrophin promoter 8 by a constitutively active Eis-transcription factor. Neuromesus Disord 2003, 13: 143–150.
- 140 Ferrer A et al. Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins. Gene Therapy 2004; 11: 884–893.
- 141 Chuang IC et al. Intramuscular electroporation with the proopiomeianocortin gene in rat adjuvant arthritis. Arthritis Res Ther 2004; 6: R7-R14.
- 142 Kim JM et al. Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Therapy 2003; 18: 1216–1224.
- 143 Perez N et al. Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis. Hum Gene Ther 2002; 13: 2161–2172.
- 144 Saidenberg-Kermanac'h N et al. Efficacy of interleukin-10 gene electrotransfur into skeletal muscle in mice with collageninduced arthritis. J Cene Med 2003; 5: 164–171.
- 145 Bloquel C, Fabre E, Bureau MF, Scherman D. Plasmid DNA electromansfur for intracellular and secreted proteins expression: new methodological developments and applications. J Com Med 2004; 6 Guppl 1): S11-S23.
- 146 Kishimoto KN, Watanabe Y, Nakamura H, Kokubun S. Ectopic bone formation by electroporatic transfer of bone morphogenetic protein 4 gene. Bone 2002; 31: 340–347.
- 147 Mager TR et al. Gene therapy of erectile dysfunction in the rat with pentle neuronal nitric oxide synthase. Biol Reprod 2002; 67: 1033–1041.

- 148 Yasui A et al. Elevated gastrin secretion by in vise gene electroporation in skeletal muscle. Int J Mol Med 2001; 8: 489-494.
- 149 Tanaka Tet al. In vivo gene transfer of hepatocyte growth factor to skeletal muscle prevents changes in rat kidneys after 5/6 nephrectomy. Am J Transplant 2002; 2: 828–836
- 150 Xue F et al. Attenuated acuse liver injury in mice by naked hepatocyte growth factor gene transfer into skeletal muscle with electroporation. Gut 2002; 50: 558–562.
- 151 Riera M et al. Intramuscular SP1017-formulated DNA electrotransfer enhances transgene expression and distributes hHGF to different rat tissues. J Gene Mat 2004; 6: 111–118.
- 152 Takahashi T et el. IGP-I gene transfer by electroporation promotes regeneration in a muscle injury model. Gene Therapy 2003; 10: 612–620.
- 153 Sakamoto T et al. Target gene transfer of tissue plasminogen activator to cornea by electric pulse inhibits Intracameral fibrin formation and corneal cloudiness. Hum Gene Ther 1999; 10-
- 154 Yomogida K, Yagura Y, Nishimune Y. Electroporated transgenerescued spermatogenesis in infertile mutant mice with a sertolicell defect. Biol Remnd 2002; 67: 712–717.
- 156 Ochiai H et al. Synthesis of human erythropoietin in vivo in the oviduct of laying hens by localized in vivo gene transfer using electroporation. Poult Sci 1998; 77: 299–302.
- 156 Draghia-Akli R et al. High-efficiency growth hormonereleasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs. FASE8 J 2003; 17: 526-528.
- 157 Khan AS et al. Maternal GFRH plasmid administration changes pitulitary cell lineage and improves progeny growth of pigs. Am J Physiol Endocrinol Metab 2003; 285: E224-E231.
- 158 Draghia-Akli R et al. Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Besgle dogs. J Anim Sci 2003, 81: 2301–2310.
- 159 http://www.cliniporator.com.